Placeholder Banner

BIO Announces 2021 Start-up Stadium Winner: Kayothera Inc.

Annual competition takes place during BIO’s International Convention

July 27, 2021
Media Contact
Theresa Brady
202.962.9235

The Biotechnology Innovation Organization (BIO) today announced that Kayothera Inc. is the winner of the Start-up Stadium competition held during BIO Digital in June. Pre-recorded presentation videos submitted by 16 finalists were evaluated by expert judges with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors. The 2021 Start-Up Stadium also featured two live sessions for finalists to present quick pitches on a virtual stage and network with judges and BIO Digital attendees. One winner was chosen across four focus areas: Diagnostics, Food and Agriculture, Platform Technology, and Therapeutics and Vaccines. Competitors from around the globe were judged on the strength of their commercially viable cutting-edge technologies and therapeutic solutions.


“As part of BIO’s commitment to growing the biotechnology ecosystem, 2021 Start-Up Stadium successfully increased awareness of these 16 innovative start-up finalists to hundreds of potential investors and development partners,” said Bernard V. Fallon, BIO’s Managing Director of Industry Research, Investor Outreach, and Education.  “Given the diversity of exciting technologies presented and in biotech investors’ specialties, BIO has already received feedback on dozens of equity investment conversations for finalists proceeding as outputs from the Start-Up Stadium contest, beyond the prize benefits that will go to this year’s one winning company, Kayothera.”


The winning company receives a one-year membership at BIO and a “fast-track” accelerator application and nomination into the final selection phase for up to a $10,000 sequencing grant (Illumina Accelerator).

"The start-up stadium was a fantastic opportunity to craft Kayothera's narrative while reaching a broad audience of stakeholders in the cancer immunotherapy field," noted Mark Esposito, CEO of Kayothera Inc. "We made several high-value investor introductions through the Start-up stadium that have led to fruitful discussions since the event."

A full list of 2021 Start-Up Stadium participants and judges can be found here.

###

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…